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Tendon developmentre well-established regulators of muscle development. In this report, we describe
the cloning of multiple splicing isoforms of the XMEF2A and XMEF2C encoding genes, differentially
expressed during Xenopus development. Using whole-mount in situ hybridization, we found that the
accumulation of XMEF2C mRNA in the tadpole stages was restricted to intersomitic regions and to the
peripheral edges of hypaxial and cranial muscle masses in contrast to XMEF2A and XMEF2D, characterized by
a continuous muscle cell expression. The XMEF2C positive cells express the bHLH transcription factor,
Xscleraxis, known as a speciﬁc marker for tendons. Gain of function experiments revealed that the use of a
hormone-inducible XMEF2C construct is able to induce Xscleraxis expression. Furthermore, XMEF2C speci-
ﬁcally cooperates with Xscleraxis to induce tenascin C and betaig-h3, two genes preferentially expressed in
Xenopus larval tendons. These ﬁndings 1) highlight a previously unappreciated and speciﬁc role for XMEF2C
in tendon development and 2) identify a novel gene transactivation pathway where MEF2C cooperates with
the bHLH protein, Xscleraxis, to activate speciﬁc gene expression.
© 2009 Elsevier Inc. All rights reserved.IntroductionThe myocyte enhancer factor 2 (MEF2) family of MADS (MCMI,
agamous, deﬁciens, serum response factor)-box transcription factors
has four members in vertebrates, MEF2A, -B, -C and -D. Each MEF2
gene gives rise to multiple isoforms through alternative splicing
(Black and Olson, 1998). MEF2 proteins bind to a conserved A/T-rich
sequence known as a MEF2 site as homo- and hetero-dimers and
combinatorially through protein–protein interactions with other
transcription factors, to function as both positive and negative regula-
tors of speciﬁc sets of target genes. The four MEF2 genes exhibit
overlapping but distinct expression patterns in embryonic and adult
tissues (Edmondson et al., 1994) and play a pivotal role in morpho-
genesis and myogenesis of skeletal, cardiac and smooth muscle cell
differentiation. These transcription factors regulate also neuronal and
immune cell differentiation (Potthoff and Olson, 2007). MEF2 proteins
bind directly to the promoters or enhancers of the majority of muscle
speciﬁc genes and interact with members of the MyoD family of basic
helix–loop–helix (bHLH) proteins to activate the skeletal muscle
differentiation program (Naya and Olson,1999; Paris et al., 2004; Blais
et al., 2005). Murine gene disruption studies provide genetic evidence
for a discrete speciﬁc function of each MEF2 isotype. Thus, Mef2c null
mice die from embryonic day 9.5 from abnormal cardiovascular(C. Chanoine).
l rights reserved.development (Lin et al., 1997, 1998) whereas Mef2a null mice die
perinatally from a spectrum of heart defects (Naya et al., 2002).
However, distinct roles for each MEF2 gene still remain to be fully
elucidated. In mice, two unexpected roles for MEF2C have been
recently identiﬁed in both chondrocyte hypertrophy (Arnold et al.,
2007) and craniofacial development (Verzi et al., 2007).
In Xenopus, twoMEF2 cDNAs, SL1 (MEF2D) and SL2 (MEF2A), have
beenpreviously characterized (Chambers et al.,1994), but the function
of MEF2C remains unknown. In this report, we describe the cloning of
multiple splicing isoforms of the XMEF2A and XMEF2C encoding
genes, differentially expressed during development and we show that
the accumulation of XMEF2C mRNA in the tadpole stages was restric-
ted to intersomitic regions and to the peripheral edges of hypaxial and
cranial muscle masses. These cells express the bHLH transcription
factor, Xscleraxis, a speciﬁc marker for tendons and ligaments
(Schweitzer et al., 2001). Most of these cells express tenascin C and
tenomodulin, two known structural markers for tendons (Tozer and
Duprez, 2005), but also betaig-h3, a connective tissue expressed gene
(Ferguson et al., 2003). We show that the use of a hormone-inducible
XMEF2C construct is able to induce Xscleraxis expression. Further-
more, XMEF2C speciﬁcally cooperates with Xscleraxis to induce
tenascin C and betaig-h3, two genes preferentially expressed in Xe-
nopus larval tendons. These ﬁndings highlight a previously unappre-
ciated and speciﬁc role for XMEF2C in tendon development and reveal
a novel gene transactivation pathway where MEF2C cooperates with
the bHLH protein, Xscleraxis, to activate speciﬁc gene expression.
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Animals
Adult Xenopus laeviswere maintained at 20 °C in tap water and fed
twice a week.
Microinjection and dexamethasone induction
All pSP64T plasmids used for microinjection were linearized with
Xba I except for the plasmid coding for nuclear beta-galactosidase
which was linearized with Xho I. Capped mRNAs were produced in
vitro from linearized plasmids using the SP6 message machine kit
(Ambion). Xenopus embryos were injected unilaterally at the two-cell
stage at themarginal zone level with 100 to 500 pg of syntheticmRNA.
For X-gal staining, embryos were coinjected with synthetic mRNA
coding for nuclear beta-galactosidase. When embryos were injected
with hormone-inducible XMEF2C or XMEF2D mRNAs, the inductionFig. 1. Developmental expression proﬁle of different alternatively spliced exons of XMEF2A, X
gene products and developmental expression proﬁle of different alternatively spliced exons
blot. ODC was used as an internal standard control of quantiﬁcation, no variation between
recognizes the ﬁrst exonwhich is not alternatively spliced. Plasmid PCR products were used t
signal intensity after hybridizationwith the different labeled primers. (B) Schematic structur
(C) Schematic structure of different alternatively spliced XMEF2C gene products and develo
embryo, head (H) or trunk and tail regions (T). The primer “all” recognizes the MADS box
performed under the same conditions, no relevant comparison could be drawn on the basi
between different primers can be made since plasmid control can be used as internal con
Comparison of amino acid sequences for Xenopus (X), human (H) and mouse (M) alternativ
designs lysine 391 and Serine 396 in exon γ of human sequence.by 10 μM dexamethasone (Sigma) was performed at stage 20 until
embryos were ﬁxed at stages 30–32.
Cloning of XMEF2 isoforms
Total RNAwas extractedwith amini RNAeasy kit (Quiagen) and the
ﬁrst strand cDNA was synthesized by Impront II reverse transcriptase
(Promega) at 37 °C for 1 h with oligo(dT) priming from 1 μg total RNA
from stage 15 and 40 embryos. PCRwas performed using a Taq and Pfu
polymerase mix. Xscleraxis cDNAwas ampliﬁed with sens 5′-GAGAG-
TTCCCAGCAGTTGGCA-3′ and antisens 5′-AGGAATGTCCATTCTTCCC-
TCA-3′ primers which were designed from Xenopus tropicalis genomic
sequence. The MEF2 isoforms were obtained with the following
primers (sense and antisense respectively): 5′-AAAGTTGCTG-
TAGCTGGCAA-3′ and 5′-TACACTGAGGCCTAATGCAT-3′ for XMEF2A,
5′-GGTGCCCAAGTAGAGCAGAG-3′ and 5′-GGTCTGCCACTTTCGGGCAA-
3′ for XMEF2C and 5′-TTCACTGCAAGGTCTTCGCT-3′ and 5′-TTTGAG-
CAAGAGGTAAGGCA-3′ for XMEF2D. PCR products were ligated intoMEF2D and XMEF2C. (A) Schematic structure of different alternatively spliced XMEF2A
(MADS box, α1, α2, retained intron) by semi-quantitative PCR, submitted to Southern
different stages was observed after hybridization (data not shown). The primer “all”
o check the hybridization reaction speciﬁcity and as internal standard for comparison of
e of the XMEF2D gene product and developmental expression proﬁle of XMEF2DmRNA.
pmental expression proﬁle of different alternatively spliced exons (δ, β and γ) in whole
sequence which is not alternatively spliced. Since the PCR reactions were not exactly
s of the hybridization signal intensity between distinct blots for XMEF2C. Comparison
trol for signal intensity. The numbers refer to the developmental stages. st, stage. (D)
ely spliced exons of MEF2C. Variations in amino acid sequence are underlined. Asterisks
394 B. della Gaspera et al. / Developmental Biology 328 (2009) 392–402pGEMT vector (Promega) and numerous clones were fully sequenced
(MWG biotech service). The nucleotide sequences of Xscleraxis cDNA
and XMEF2A isoformswere deposited into the GenBank databasewith
accession numbers EU867769 (Xscleraxis), EU867764 (XMEF2A
α12b), EU867765 (XMEF2A α2), EU867766 (XMEF2A MADSbox),
EU867767 (XMEF2A α1c) and EU867768 (XMEF2A α1b).
Constructs
For expression in Xenopus embryos, all constructs were subcloned
into pSP64T-Flag to generate a C-terminal Flag tagged protein. The
PSP64T-XmyoDF (F for Flag) plasmid has already been described
(Charbonnier et al., 2002). The full-length XMEF2A, XMEF2C,
XMEF2D, and Xscleraxis cDNAs were inserted by “PCR-directed
cloning”, a method developed in our laboratory (Charbonnier et al.,
2003) and by (Geiser et al., 2001). This quick PCR protocol, which is an
extension of the quick change mutagenesis method (Stratagene),
allows the insertion or exchange of a PCR-fragment anywhere in a
plasmid target. To generate a dexamethasone-inductible XMEF2C or
XMEF2D protein (XMEF2CGRF or XMEF2DGRF), the Glucocorticoid-
binding domain of the mouse glucocorticoid receptor (amino acids
519 to 783) was added at the C-terminal position of pSP64T-MEF2CF
or PSP64T-MEF2DF between the last coding codon and the ﬁrst Flag
epitope codon. All plasmids were fully sequenced.
RT-PCR expression analysis
First strand cDNAs were synthesized by Impront II reverse trans-
criptase (Promega) with oligo(dT) priming from 1 μg total RNAFig. 2. (A) Whole-mount in situ hybridization with labeled antisense probes against XME
developmental stages. The anterior side of the embryos is on the left. Lateral view for all emb
anterior view for XMEF2C stage 19. (B) XMEF2A, XMEF2D and XMEF2C expression at stages
on the left. ba, brachial arches; cm, cranio-facial muscle; fhr, frontal head region; nc, neuraextracted from embryos at different stages. Embryos and larvae were
staged according to Nieuwkoop and Faber (1994). PCRs were
performed with a Taq and Pfu mix in semi-quantitative ampliﬁcation
conditions (25 cycles) and ODC was used as an internal standard.
Controls for PCR and hybridization were performed using pGEMT
plasmids carrying different MEF2 isoform cDNAs, as template. The
oligonucleotide primers are those described in the section “Cloning
of XMEF2 isoforms”. PCR products were separated on 1% agarose
gels, denaturated with 0.4 M NaOH during transfer onto a HyBond-N
Nylon membrane (Amersham Pharmacia Biotech) and hybridized
overnight at 50 °C with 10 ng of labeled primers in 10 mM
phosphate buffer pH 7 containing 5× SSC, 10× Denhart's solution
and 0.1% SDS. Primers were labeled at their 3′ ends by addition of
digoxigenin-11-ddUTP (Roche) using terminal transferase according
to the manufacturer's recommendations (Promega). The blots were
washed at room temperature in a buffer containing 2× SSC, 0.1% SDS
for 30 min and then 10 min with PBS. The peroxidase-conjugated
anti-digoxigenin antibody (Roche) was added to the blocking buffer
(10% inactivated sheep serum, 1% Roche blocking reagent, 0.1%
tween-20 in MAB buffer pH 7.4) for 1 h at a 1:2000 dilution. Signals
were detected using ECL detection reagents (Amersham Pharmacia
Biotech). After three PBS washing, the same blots were stripped in
0.1% boiled SDS and reprobed successively with other exon-speciﬁc
labeled-primers.
Real-time PCR using an ABI Prism 7700 (Applied Biosystems Inc.,
Foster City, CA) and ﬂuorescence detection were performed in 384-
well plates using SYBR Green buffer (Applied Biosystems). Primer
concentrations were optimized to yield the lowest concentration of
primers that gave the same Ct values as recommended by AppliedF2D, XMEF2A and XMEF2C during embryonic development. The numbers refer to the
ryos except dorsal view for XMEF2D stages 12, 16 and 20; XMEF2A stages 16 and 20; and
37–38 in head muscle anlagens as indicated by XMRF4 mRNAs localization. Lateral view
l crest; h, heart; hm, hypaxial muscles. Arrowhead: hypaxial migratory cells.
Fig. 3. Comparison of the localization of XMEF2C mRNA with the muscle markers by
whole-mount in situ hybridization. (A) Expression of MyHC E3 and XMEF2C (left and
middle respectively) at stages 39–40 (left). Double in situ hybridization of XMEF2C
(purple) andE3 (blue) shows that XMEF2CmRNA is expressed in cells localized between
streams of hypaxial muscle (right, stage 41). (B) XMEF2C is expressed in intersomitic
space. Comparison of hybridization with XMRF4 (left top), XMEF2C (left middle), and
cohybridizationwith XMRF4 and XMEF2C (left bottom). The thin XMEF2C expression is
distinct from the thick XMRF4 expression. Double in situ hybridization shows that
XMRF4 or XMEF2AmRNA (purple) accumulates around the large and centrally localized
nuclei ofmononucleatedmuscle cells (Kiełbówna, andDaczewska, 2005)while XMEF2C
mRNA (blue) is restricted to intersomitic space. Frontal section indicates that XMEF2C
mRNA is found throughout the intersomitic space (C) XMEF2C is strongly expressed in
the head at the muscle-border zone corresponding to connective tissue associated with
muscle at stage 41. XMEF2A and XMEF2D are expressed in muscle cells as indicated by
XMRF4 expression. (D) Comparison of the localization of XMEF2C mRNA and pax3
mRNA at stages 37–38. Lateral view shows that pax3 mRNA (left) is more concentrated
in the anterior and posterior side of somiteswhileMEF2CmRNA (middle) is restricted to
the intersomitic region. Frontal section (right) indicates that pax3 expression is limited
to the external border of somites. The probe is indicated in each image. Arrows indicate
XMEF2C expression except in D where they show intersomitic space.
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with each real-time RT-PCR experiment to verify that there was no
genomic DNA contamination. PCR ampliﬁcation was performed (in
triplicate) as a singleplex reaction in a total reaction volume of 10 μl.
The reactionmixture consisted of 5 μl of SYBRGreen template (Applied
Biosystems) forward and reverse primers (ODC: 5′- TGCTGCCAATGA-
CAAAACTC-3′ and 5′-GGTCCCCAAATGCTGCTCGA-3′; Xscleraxis: 5′-
CCAGCAACCCAAACTCATCT-3′ and 5′-ACTCCATTCGGGTGTTCTTG-3′)
as determined from the prior optimization procedure, nuclease-free
water and cDNA. The PCR parameters were the following: incubation
for one cycle at 50 °C for 2 min to prevent ampliﬁcation of carryover
DNA followed by denaturation at 94 °C for 15 min and then ampli-
ﬁcation for 40 cycles of 95 °C/15 s and 60 °C/1 min. Ampliﬁcation
products were routinely checked using dissociation curve software
(Applied Biosystems) and by gel electrophoresis on a 1.5% agarose gel,
then visualized under UV light after 0.05% ethidium bromide staining
to conﬁrm the size of the DNA fragment and that only one product was
formed. Samples were compared using the relative Ct method, where
the amount of target normalized to the amount of endogenous control
and relative to the control sample is given by 2−ΔΔCt.
Western blot
Western blotting experiments with anti-Flag antibodies have
already been described (Becker et al., 2003).
Whole-mount in situ hybridization, X-gal staining and embryos section
The embryo ﬁxation and whole-mount in situ hybridization with
digoxigenin-labeled antisense RNA probes were carried out as
previously described (Della Gaspera et al., 2006). Probes for
whole-mount in situ hybridization were prepared as follows. Probes
were ampliﬁed from reverse transcribed cDNA from total RNA of
stage 20 or 45 embryos and cloned into the pGEMT vector. Targeted
cDNAs were ampliﬁed by PCR with the following primers (sense and
antisense respectively): 5′-CTCGGGGACACGTGCGGGGACG-3′ and 5′-
AGGAATGTCCATTCTTCCCTCA-3′ for Xscleraxis, 5′-cgcccagaaatgga-
cagcct-3′ and 5′-CTTTCAAAGAGGGATCTGTA-3′ for XMEF2A, 5′-
taagcagtgcagacctatca-3′ and 5′-GGTCTGCCACTTTCGGGCAA-3′ for
XMEF2C, 5′-aaccccatcaacatcagcat-3′ and 5′-TTTGAGCAAGAGG-
TAAGGCA-3′ for XMEF2D, 5′-GCAGATGAGGAACCCTTGTC-3′ and
5′-ATGTCACGTCAGTGCAACAAG-3′ for XMRF4, 5′-GAGGGACCAA-
GAGGAAAGGT-3′ and 5′-TGGTTATTCCGTAAACGCTT-3′ for desmin,
5′-GCCCTTCCAAGAGGAGACTT-3′ and 5′-CACGCGACACATGAAATCAC-3′
for betaig-h3, 5′-CTGGTACAGCGGGAGATTCC-3′ and 5′-GCAGAATTG-
TATTCCTGCAGG-3′ for tenascin C, 5′-GATACACATCATTGTACGGG-3′ and
5′-AGTTACCAACAGAACATAAC-3′ for pax3, 5′-gaagaaggccatcttgctac-3′
and 5′-GATTTGAGAGTCCTCCTTGG-3′ for Col1a2, 5′-CACAAGGAA-
CACGGCAAAGT-3′ and 5′-GTCACAGTCGGGGTTGTAGT-3′ for Col5a1, 5′-
AGAACAGGACCTCCAGGATC-3′ and 5′-GCAGCAGGCTTTAATGCAGA-3′
for Col12a1, 5′-CCTCCTCACTAACAGATTCTG-3′ and 5′-TCGACCCAA-
CATTCTGGCAACC-3′ for tenomodulin. Primers were designed from Xe-
nopus tropicalis mRNA sequence for tenomodulin. No signal was
detected using sense probes. The double in situ hybridization was
performedwith digoxigenin- (for XMEF2C) and ﬂuorescein-labeled (for
MyHC E3, XMRF4, XMEF2A and Xscleraxis) RNA probes, and two
successive color reactions (BM-purple, Roche and BCIP, Sigma)
separated by heat inactivation (65 °C, 30 min) of alkaline phosphatase.
For X-gal staining, embryos were ﬁxed in MEMFA 10 min before color
reaction. After staining, embryoswere ﬁxed 1 h and kept inmethanol at
−20 °C before hybridization. For each experiment, at least 40 injected
embryos were tested. At least 70% of X-gal-positive embryos show the
indicated phenotype. For frontal sections, whole mount in situ staining
wasperformedﬁrst. Embryoswereﬁxed for 2h inMEMFA, embedded in
parafﬁn, and sectioned using a microtome. The sections were cut at a
thickness of 15 μm.Results
Identiﬁcation of multiple XMEF2 splicing isoforms
To identify XMEF2 isoforms in Xenopus, we retrieved cDNA
sequence from data bank, and designed primers to amplify and
clone cDNA from stages 15 and 35. Here, we report the isolation and
characterization of cDNA encoding splicing variants of XMEF2A and
XMEF2C whose structure is depicted in Fig. 1. In mammals, three
396 B. della Gaspera et al. / Developmental Biology 328 (2009) 392–402major exons are alternatively spliced in MEF2A, MEF2D or MEF2C: the
two mutually exclusive exons α1 and α2, a short exon β and an exon
γ which is only spliced in some MEF2C gene transcripts (Zhu and
Gulick, 2004). The six identiﬁed XMEF2A variants present some
speciﬁc characteristics in comparison to those identiﬁed in mammals
(Fig. 1A). Two isoforms (XMEF2A α12 and α12b) possess the two
normally mutually exclusive exons α1 and α2. Two variants (XMEF2A
α1b and XMEF2A α12b) show particular splicing events: one
(XMEF2A α1b) with a new spliced exon, that we term ɛ, and the
other one (XMEF2A α12b) with spliced exons coding for the MADS
box and the MEF2 domain. Two other variants (XMEF2A α1c and
XMEF2A MADSbox) were characterized by the introduction of a
premature stop codon: the ﬁrst one (XMEF2A α1c) resulting from a
large splicing event that shifts the open reading frame and the second
one (XMEF2A MADSbox) resulting from a putative retained intron
sequence that stops the open reading frame. The predicted amino
acid sequence of the identiﬁed XMEF2A isoforms is presented in the
supplementary data.
For XMEF2C, three exons were alternatively spliced: the two
corresponding mammals exons β and γ and also another one that
we term δ (Fig. 1C). No variant with the corresponding mammal
exon α2 was identiﬁed and the exon α1 was expressed in every
identiﬁed splicing variant. Six different combinations have been
identiﬁed (δ+β−γ−; δ−β+γ+; δ−β−γ+; δ+β−γ+; δ−β−γ+;
and δ+β+γ−) . The Xenopus, mouse and human amino acid
sequences of the three XMEF2C alternatively spliced exons (β, δ
and γ) were aligned (Fig. 1D).
No XMEF2D alternatively spliced variants was detected, and we
identiﬁed a single isoform, which corresponds to the mammal α1, β
form (Fig. 1B). Our study could not provide a complete screening of
splicing variants but it allowed us to identify themajor ones expressed
during embryonic development. Other putative isoforms could be
expressed at a lower level or later during development.
Differential developmental and regional expression of XMEF2
alternatively spliced exons
By semi-quantitative RT-PCR, we found the same pattern of
expression for XMEF2A and XMEF2D (Figs. 1A and B) as previously
shown by RNase protection assay (Chambers et al., 1994): both
transcripts are maternal, present in unfertilized eggs. Zygotic XMEF2A
transcription seems to begin at stages 13–15 as the ﬁrst wave of
muscle ﬁbers differentiates and muscle structure markers start to
accumulate (data not shown and reviewed in Chanoine and Hardy,
2003). XMEF2C transcripts are also slightly inherited from the unfer-
tilized egg (data not shown), and is expressed by the zygote from
stage 13 (Fig. 1C). XMEF2A and XMEF2C transcripts progressively
increase until stages 26–27, whereas XMEF2D mRNA expression
decreases from stage 23.
The pattern of expression of the XMEF2A and XMEF2C alter-
natively spliced exons was also determined by RT-PCR-ampliﬁcation
of full-length coding region followed by hybridization with speciﬁc
labeled-primers of each exon. The XMEF2A hybridizations (Fig. 1A)
showed that the different alternatively spliced exons are characte-Fig. 4. Comparison of the localization of XMEF2C and Xscleraxis mRNA bywhole-mount in sit
in the border of muscle masses of the head while scleraxis expression is faint and more diff
dorsal views (g and h) indicate that XMEF2C expression is restricted to the intersomitic spac
region, XMEF2CmRNA begins to be expressed at stage 40 from the bottom (i) to the top (k) o
stages (j and l). (B) XMEF2C and Xscleraxis are largely colocalized in stage 43 embryo in the b
of the head region, (d) and (e): lateral view of the head, (f) and (g): lateral view of the hypax
connective tissue associatedwith hypaxial muscles. (C) Scleraxis mRNA begins to be expresse
and Xscleraxis, and cohybridized with XMRF4 and Xscleraxis. XMRF4 mRNA accumulates aro
mononucleated and span the entire somite. The myotome presents a convex side on dor
segments. The thin XMEF2C and Xscleraxis expression are distinct from the thick MRF4 exp
magniﬁcation of dorsal view in the middle and lateral view at the bottom. The probe is indic
single (a–d) or double (e–g) in situ hybridization of XMEF2C mRNA (blue) with XMRF4, XM
XMEF2C mRNA is not colocalized with XMRF4 and XMEF2A mRNA while Xscleraxis beginsrized by a similar developmental pattern of expression except for
two exons: the α1 exon was less present than the α2 and the MADS
box exons in the maternal pool of XMEF2A mRNA. The XMEF2Aα c
isoform, which was detected with a speciﬁc primer of the putative
retained intron, was exclusively of zygotic expression and accumu-
lated when muscle cells differentiate. In the case of XMEF2C (Fig.
1C), only exons δ and γ were detected in a signiﬁcant proportion in
all developmental stages, in the head and tail regions. In contrast,
the exon β was barely detected except at stage 36 in the head
region.
XMEF2C marks the peripheral edges of muscle cell masses
XMEF2D transcripts were precociously detected by whole-mount
in situ hybridization in presomitic mesoderm from the gastrula
stage 11 (Fig. 2A). At stages 16–20, XMEF2D mRNA strongly accumu-
lates in the undifferentiated mesoderm of the caudal region and in the
rostral myotomes initiating their full differentiation program. From
stages 25–30, XMEF2D transcripts were detected in the posterior
unsegmented mesoderm and declined from the anterior somites that
differentiate ﬁrst. Later XMEF2D mRNA strongly accumulates in the
heart, in both cranial and hypaxial muscles, but also in some regions
of the head and slightly in brachial arches. More belatedly, XMEF2A
transcripts accumulate at a detectable level in somite mesoderm at
stage 16 (Fig. 2A) when the myogenic regulatory factor XMRF4, a
relatively late-activated muscle gene, begins to be expressed (Della
Gaspera et al., 2006). In the following stages, XMEF2A mRNA
accumulation extends posteriorly in the myotome accounting for
the anterior to posterior muscle mesoderm differentiation. From stage
28, XMEF2A mRNA is also expressed in some regions of the head and
accumulates in the cranial muscles as well as in the hypaxial muscles
from tadpole stage 40. From stage 19, XMEF2C transcripts begin to
accumulate in the forming and migrating neural crests (Fig. 2A), but
not in muscle cells. XMEF2C is further expressed in the somite region,
slightly at stage 30 and clearly detectable from stage 34. XMEF2C
transcripts are also detected in the heart, in migratory hypaxial cells
and in some regions of the head (Fig. 2A, see stage 36). From stage 37,
XMEF2C mRNA also accumulates in cranial muscles (Fig. 2B) and
surprisingly in the peripheral edges of the ventral (hypaxial) muscles
(Fig. 2A, stage 40). To better identify XMEF2C expression in the
hypaxial region, we compared the accumulation of MyHC E3 and
XMEF2C mRNA. XMEF2C transcripts are then restricted to the
peripheral edges of the hypaxial muscles at stage 40 (Fig. 3A).
Likewise, XMEF2C mRNA is strictly detected in intersomitic regions
and does not extend into the myotomal regions of the somites
expressing XMEF2A (Fig. 3B) and the muscle speciﬁc myogenic bHLH
factor, XMRF4 (Figs. 3B and 4C). The MyHC is not either expressed in
the intersomitic space (Martin and Harland, 2006). At the level of the
head, the three members of the MEF2 family, XMEF2A, XMEF2D and
XMEF2C, are co-expressed at stage 37 in XMRF4 positive myogenic
cells (Fig. 2B). From stage 40, XMEF2C mRNA becomes restricted to
the peripheral edges of the muscles, whereas XMEF2A and XMEF2D
remains expressed in muscle cells (Fig. 3C). Expression domains of
pax3, a marker of myogenic precursor cells and XMEF2C were alsou hybridization. (A) Stage 38 (a–d). At stage 40 (e and f) XMEF2C begins to be expressed
use around muscle masses. Lateral view (a and b). Ventral view (c–f). In somite region,
e while Xscleraxis expression appears faint and more diffuse. In lateral view of hypaxial
f connective tissue betweenmuscle cells. No Xscleraxis expressionwas detected at these
orders of muscle masses as indicated byMRF4 staining (c). (a), (b) and (c): ventral view
ial region. The probe is indicated in each image. Arrows indicate Scleraxis expression in
d in intersomitic space at stage 43. Embryos have been hybridized with XMEF2C, XMRF4
und the large and centrally localized nuclei of muscle cells. At this stage, muscle cells are
sal view. Arrow head indicates the intersomitic space between two convex myotome
ression and is localized between the convex myotome. Dorsal view on the top, higher
ated under each image. Arrows indicate Xscleraxis expression in intersomitic space. (D)
EF2A or Xscleraxis mRNA (purple) in the ventral view of the head embryo at stage 41.
to be strongly expressed in most of the XMEF2C expressing cells.
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398 B. della Gaspera et al. / Developmental Biology 328 (2009) 392–402compared in the somites: the lateral view (Fig. 3D) shows an
extended pattern of pax3 expression in the border of anterior and
posterior somites. In contrast, XMEF2C is strictly expressed in the
intersomitic region. In the frontal section view, MEF2C expression is
quite distinct from pax3 expression. XMEF2C was expressed along the
transversal lane between somites (Fig. 3B) while pax3 was expressed
in the lateral edge of the somites (Fig. 3D), corresponding to the
dermomyotome (Grimaldi et al., 2004). No pax3 staining was
observed inside the somites at this stage, showing that MEF2C
expression was not associated with differentiated muscle cells, nor
with pax3 positive myogenic precursor cells.
XMEF2C is coexpressed with Xscleraxis in cells with tendon
molecular signature
In contrast to XMEF2A and XMEF2D, XMEF2C accumulates in a
non-myogenic cell population associated to muscle cells in the head,
hypaxial and intersomitic regions. For this, we focused our analysis on
the bHLH factor, Xscleraxis, which is expressed in progenitors of theFig. 5. Comparison of the localization of XMEF2C, Xscleraxis, betaig-h3, tenascin C and tenom
expressed in connective tissue associated with hypaxial muscle at stage 41. (B) XMEF2C, Xscle
head region (ventral view, top) intersomitic space as indicated by staining between the conv
expresses XMEF2C, Xscleraxis, betaig-h3 and tenascin C, but we cannot detect tenomodulin
intersomitic space at stage 45 (D) Comparison of MEF2C and scleraxis mRNA accumulation 3
appears stronger. Arrows indicate connective tissue associated with hypaxial muscles expreaxial tendons located in the intersomitic regions in the mouse embryo
(Brent et al., 2003). From stage 40, when XMEF2C began to
accumulate in the peripheral edge of head muscles (Figs. 4A and
3C), a whole-mount in situ hybridization showed that Xscleraxis
expression is faint and diffuses around muscle masses (Fig. 4A). At
stages 40–41, whereas XMEF2C strongly accumulated in the periph-
eral edge of myotomal and hypaxial muscles (Fig. 4A), the accumula-
tion of Xscleraxis appears faint and diffuses in the somite while no
Xscleraxis expression was detected in the hypaxial region (Fig. 4A).
XMEF2C and Xscleraxis transcripts are co-localized at stage 43 in the
peripheral edge of head, hypaxial andmyotomal muscles (Figs. 4B–D).
At stage 43, Xscleraxis expression is strong at the top of intersomitic
region like XMEF2C, but is faint through the somites and becomes
higher at later stages (stage 45) (Fig. 5C) and 3 days after the
beginning of feeding (Fig. 5D). Double in situ hybridization of XMEF2C
with XMRF4, XMEF2A or Xscleraxis mRNA (Figs. 4C and D) clearly
showed that XMEF2C mRNA is not colocalized with the muscle
markers, XMRF4 and XMEF2A and conﬁrm that Xscleraxis is strongly
expressed in most of the XMEF2C expressing cells (Fig. 4D). To furtherodulin mRNA by whole-mount in situ hybridization. (A) Betaig-h3 mRNA begins to be
raxis, betaig-h3, tenascin C and tenomodulinmRNA are largely colocalized at stage 45 in
ex myotome (dorsal view, middle). Connective tissue associated with hypaxial muscles
mRNA (lateral view, bottom). (C) Col1a2, col5a1 and col12a1 mRNA is also expressed in
days after feeding. MEF2C mRNA is always expressed at this stage while scleraxis mRNA
ssion. Numbers indicate developmental stages.
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structural genes speciﬁcally expressed in this non-myogenic cell
population.
We screened extracellular matrix genes potentially expressed in
tendon cells by whole-mount in situ hybridization experiments. We
identiﬁed the betaig-h3 gene, encoding for a cell adhesion protein
accumulated in collagen-rich tissues and tendons in mouse (Ferguson
et al., 2003), as a structural gene expressed in the XMEF2C/Xscleraxis-
positive cell population. Betaig-h3 is weakly expressed from stage 41
in the hypaxial region (Fig. 5A) and it further accumulates in the
intersomitic and head XMEF2C/Xscleraxis-positive cells at stage 45
(Fig. 5B). At this stage, these cells express also tenascin C (Fig. 5B) and
begin to accumulate tenomodulin mRNA at least in the head and
intersomitic region (Fig. 5B). These two genes are known to be pre-
ferentially expressed in tenocytes (Tozer and Duprez, 2005). XMEF2C
is the ﬁrst transcription factor expressed in these cells, followed by
Xscleraxis (Fig. 4). At stage 45, the majority of these cells express
equally betaig-h3, tenascin C and tenomodulin (Fig. 5B). The collagen
chain, 1a2, 5a1 and 12a1 often associated with tendon cell line (Tozer
and Duprez, 2005) are equally found in this region, between two
somitic segments (Fig. 5C). We conclude that these cells located in the
periphery of muscle masses share largely the same molecular
signature as tendon cells. This observation points out the fact that
XMEF2C could play a precocious and regulatory role in larval tendon
development.
XMEF2C activates Xscleraxis and both cooperate to ectopically induce
betaig-h3 and tenascin C
To test the early effect of XMEF2C, we overexpressed each XMEF2
gene in Xenopus embryos, in combination or not with XMyoD since it
is well established that MEF2 proteins interact with members of the
MyoD family to activate the skeletal muscle differentiation program
(Molkentin and Olson, 1996). Synthetic RNAs were microinjected into
a single blastomere of two-cell stage Xenopus embryos. The embryos
were analyzed at stages 18–19 using whole-mount in situ hybridiza-
tion for desmin expression, a classical muscle gene marker. As pre-
viously observed for actin and myosin heavy chain (Ludolph et al.,
1994), in vivo overexpression of XMyoD induces an ectopic expression
of desmin whereas co-injection of XMyoD with one member of the
MEF2 family, XMEF2A (XMEF2Aα12), XMEF2D or XMEF2C (δ+β−γ+
isoform) strongly up-regulates the ectopic expression of desmin (Fig.
6B), conﬁrming that MyoD and MEF2 proteins synergistically induce
myogenesis (Black and Olson,1998).While overexpression of XMEF2A
or XMEF2D alone does not activate the desmin gene, an injection of
XMEF2C RNA alone reduces the accumulation of desmin transcripts
(Fig. 6B) in myotome of the embryo. Therefore, in order to analyze the
regulation of Xscleraxis expression in later stages of development, weFig. 6. (A) Western blot of late gastrula embryos injected into the two blastomeres at the
Proteins were detected with anti-ﬂag antibody. (B) Embryos were injected unilaterally at the
western blot. Embryos were ﬁxed at stages 18–19 and submitted to whole-mount in situ hy
encoding the lineage tracer β-galactosidase (blue) was used to identify the injected side of
ectopic expression of desmin is easily detected (a–d).used a hormone-inducible XMEF2C construct (Hollenberg et al.,
1993), MEF2CGRF. Embryos were injected unilaterally at the two-cell
stage, induced by 10 μM dexamethasone at stage 20, and submitted to
whole-mount in situ hybridization for Xscleraxis at stages 30–31.
Xscleraxis is weakly expressed at this stage (Fig. 7B). MEF2CGRF
efﬁciently induces Xscleraxis expression in the somites of the injected
side (Fig. 7C). Real-time PCR analyses fully conﬁrmed these results
and indicated that the level of Xscleraxis transcripts increases more
than 3.5-fold in the MEF2CGRF injected embryos in comparison to
mock-injected controls (Fig. 7C). In contrast, Xscleraxis expression
was not induced in the MEF2DGRF injected embryos (Fig. 7C).
To test the effects of XMEF2C and/or Xscleraxis on the accumula-
tion of tendon target-genes, MEF2CGRF, scleraxisF or a combination of
both were microinjected unilaterally at the two-cell stage, induced by
dexamethasone at stage 20 and submitted to whole-mount in situ
hybridization for betaig-h3 (Fig. 7E), tenascin C (Fig. 7G) and
tenomodulin expression at stages 30–31. Betaig-h3 expression begins
at stage 31 in both dorsal part of the somite and intersomitic region
(Fig. 7D). An injection of MEF2CGRF and its induction at stage 20 has
little effect on betaig-h3 expression, whereas Xscleraxis overexpres-
sion enhances betaig-h3 expression in the injected side (Fig. 7E). A
co-injection of MEF2CGRF and scleraxisF (but not of MEF2DGRF
and scleraxisF, supplementary data) induces a strong and ectopic
expression of betaig-h3 in thewhole somitic region (Fig. 7E). At stages
30–32, tenacin C mRNA accumulates in the somitic (not intersomitic)
region as shown in Fig. 7F, as previously reported (Umbhauer et al.,
1992). Microinjection of MEF2CGRF or scleraxisF transcripts alone
efﬁciently reduces tenascin C gene expression whereas a co-injection
of MEF2CGRF and scleraxisF induces an ectopic expression of tenascin
C in thewhole somitic regions aswell as in the caudalmesodermof the
embryo at stages 30–32 (Fig. 7G). In contrast, the co-injection of
MEF2DGRF and scleraxisF is unable to induce the expression of
tenacin C (Fig. 7, supplementary data). No tenomodulin expression
was observed after injection and induction of MEF2CGRF, scleraxisF
or both (data not shown).
Discussion
We identiﬁed several splicing variants of the Xenopus MEF2A and
MEF2C gene transcripts and showed by gain-of-function experiments,
that XMEF2C, whose expression pattern differs from those of XMEF2A
and XMEF2D, has a unique role in larval tendon construction.
The evidence of conserved structural domains provides a clue to the
mechanism of the transcriptional activity of the MEF2 family: the
MADS-box and the MEF2 domain, located at the N terminus of the
MEF2 factors are responsible for DNA binding and dimerization;
speciﬁc regions in the C-terminal transactivation domain are the target
of p38 or ERK5phosphorylation sites (Kato et al.,1997;Naya andOlson,two-cell stage with 300 pg of MyoDF, 100 pg of MEF2AF, MEF2DF and MEF2CF mRNA.
two-cell stage at the level of marginal zone with the quantities of mRNA described for
bridization with desmin probe. The injected mRNAs are indicated in each image. mRNA
embryos (e–g) except for embryos injected with synthetic mRNA of MyoD where the
Fig. 7. (A) Western blot of late gastrula embryos injected into the two blastomeres at the two-cell stage with 300 pg of MEF2DGRF, MEF2CGRF or ScleraxisF synthetic mRNA.
Proteins were detected with anti-ﬂag antibody. Molecular weight markers are indicated in kilodalton. (B) Xscleraxis expression at stage 31. (C) Left: detection of Xscleraxis mRNA
by whole mount in situ hybridization after unilateral injection of MEF2CGRF synthetic mRNA (+MEF2CGRF) at the two-cell stage and induction by dexamethasone at stage 20.
Right: Detection of Xscleraxis mRNA by real-time PCR after bilateral injection of mock (mock), MEF2CGRF or MEF2DGRF synthetic mRNA at the two-cell stage and induction by
dexamethasone at stage 20. (D) Betaig-h3 expression at stage 31 (left) and comparison of betaig-h3 with XMRF4 expression (betaig-h3+MRF4) indicates that betaig-h3 is
expressed in intersomitic space (right, arrows). (E) Embryos were injected unilaterally at the two-cell stage, at the marginal zone level with the quantities of mRNA used for
western blot. Embryos were injected by MEF2CGRF synthetic mRNA (+MEF2CGRF), scleraxisF synthetic mRNA (+scleraxisF) or by a mix of MEF2CGRF and scleraxisF synthetic
mRNA (+MEF2CGRF+scleraxisF). Embryos were induced by 10 μM dexamethasone at stage 20, ﬁxed at stages 30–31 and submitted to whole-mount in situ hybridization to
detect betaig-h3. (F) Tenascin C expression at stage 32 (left) and comparison of tenascin C with XMEF2C expression (tenascin C+MEF2C) indicates that tenascin C is expressed in
somitic cells (right, arrows). (G) Embryos were injected unilaterally at the two-cell stage as described in (E) and analyzed for tenascin C expression. mRNA encoding the lineage
tracer β-galactosidase (blue) was used to identify the injected side in panels C, E and G. Inj., injected side; uninj., uninjected side. In panels C, E and G, injected side at the top,
non-injected side in the middle, and dorsal view at the bottom. No variations were observed in uninduced embryos injected by MEF2CGRF synthetic mRNA.
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XMEF2A isoforms during the ﬁrst phase of somitic development. The
biological signiﬁcance of XMEF2A isoforms still remains unclear,particularly among those lacking the transactivation domain (such as
MEF2Aα1c) or unable to bind DNA or to dimerize (such as
MEF2Aα12b). This suggests however the existence of complex
401B. della Gaspera et al. / Developmental Biology 328 (2009) 392–402regulatory networks in which these MEF2 isoforms could accurately
modulate the transcriptional activation of somitic target genes.
The 3 XMEF2 factors increase ectopic desmin expression induced
by MyoD (Fig. 6), as it was well established that MEF2C can
cooperate with MyoD to enhance desmin expression in the context
of myogenic differentiation (Li and Capetanaki, 1994). Conversely,
XMEF2C (not XMEF2A and XMEF2D) is able to inhibit desmin
expression in a particular context when injected ectopically at the
two-cell stage. Therefore, XMEF2C could have a speciﬁc function
depending on the cellular context. Furthermore, we show that
XMEF2C activates and cooperates with Xscleraxis to speciﬁcally
induce the ectopic expression of larval tendon genes, betaig-h3 and
tenascin C. XMEF2C may have some speciﬁc transcriptional proper-
ties probably located in the C-terminal domain that could afford our
observations. In the gain-of-function experiments, we systematically
used the (β−, γ+) XMEF2C variant which is the major isoform
expressed in the larvae and whose expression is sustained during
development. In the head, at stage 36, the detected XMEF2C
isoforms include the β-domain whereas the tail region expresses
only (β−) XMEF2C variants. So, we conclude that exon β is probably
expressed in cranial muscle anlagens. Indeed, in mammals, the MEF2
mRNAs containing exon β are expressed predominantly in the
striated muscles and the brain and it appears that splicing to include
β is induced during myocyte differentiation (Zhu et al., 2005). It has
been also reported that (β+) MEF2 isoforms are more robust than
(β−) forms in activating MEF2-responsive reporters (Zhu et al.,
2005), but to our knowledge there is no evidence about the potential
involvement of the β inclusion in the transactivation of a speciﬁc set
of target genes. In mammals, MEF2C is expressed predominantly as
(γ−) isoform in adult tissues and in mouse differentiating myocytes
(Zhu and Gulick, 2004). Previous reports indicated that (γ−) MEF2C
has higher transcriptional activity than (γ+) MEF2C (Zhu and
Gulick, 2004) which has a transrepression function. The γ-domain
might recruit transcriptional repressors in a phosphorylation-
dependant manner. Indeed, the phosphorylation of MEF2C at residue
S396 facilitates its sumoylation at K391, which in turn recruits
unidentiﬁed co-repressors to inhibit transcription (Kang et al.,
2006). These amino acids within the γ domain are conserved in
Xenopus, human and mice (see Fig. 1). The involvement of the β
and γ domains in speciﬁc functions of XMEF2C remains to be
determined, but it seems that the β inclusion is not necessary to
transactivate the scleraxis gene and that the presence of the γ
transrepressor domain does not block the activation of this gene.
While XMEF2A and XMEF2D were ﬁrst expressed in pre- and
somitic cells, XMEF2C transcripts strictly began to accumulate in non-
muscle cells, the premigratory cranial neural crest. In addition to
cardiac, somitic and vascular expression domains, it has been shown
that MEF2C expression is required in cranial neural crest for cranio-
facial development in zebraﬁsh (Miller et al., 2007) and mice (Verzi
et al., 2007). MEF2C was also localized in muscle cells and has been
involved in later steps of myogenic differentiation in zebraﬁsh (Hinits
and Hughes, 2007) and mice (Potthoff et al., 2007). From stage 40,
XMEF2C accumulates in the connective tissues associated withmuscle
masses, in the head, hypaxial and somitic regions even if we cannot
exclude that some pax3 positive myogenic cells could also express
XMEF2C. All XMEF2C positive cells seem to share the same molecular
properties, since they express XMEF2C, Xscleraxis, betaig-h3 and
tenascin C at stage 45. The majority of these cells also express
tenomodulin. The position and the molecular signature of these cells
let us to deﬁne them as larval tendon cells. In mice, it has been shown
that MEF2C is also expressed on the dorsal part and in the peripheral
edges of the somites whereas MEF2A, MEF2D and the myogenic bHLH
factors are expressed centrally in the somites (Edmondson et al.,
1994), suggesting also that theseMEF2C positive cells might represent
a distinct cell population. In mice, scleraxis is the earliest and most
persistent marker known for the tendon lineage (Schweitzer et al.,2001; Tozer and Duprez, 2005). In somites, scleraxis is also expressed
in the mesenchyme lining the intersomitic boundary (Schweitzer
et al., 2001) and a somitic compartment of tendon progenitors,
namely syndetome, has been identiﬁed in mice (Brent et al., 2003).
This scleraxis-positive compartment results from interactions
between the two early-formed somitic compartments, the sclerotome
and the myotome, and is induced at the sclerotome's edge in response
to FGF signaling from the adjacent myotome (Brent and Tabin, 2004).
In Xenopus, this process is less described but the analysis of somito-
genesis and the identiﬁcation of a compartment homologue of
amniote dermomyotome (Grimaldi et al., 2004) support a similar
type of organization. However, whether MEF2C and scleraxis
colocalized in mice remains unknown. Genetic analyses of cell lineage
could be used to evaluate the real contribution of somitic MEF2C
expressing cells to muscle cells and/or other cell types, like the
tendon cell lineage.
The analysis of the scleraxis (−/−) mouse phenotype (Murch-
ison et al., 2007) showed that scleraxis is not a master gene in
tendon construction, since the tendon progenitors appeared normal
in scleraxis (−/−) mice. However, scleraxis plays multiple crucial
roles in tendon differentiation and organization: the extracellular
matrix in the remained tendons of scleraxis (−/−) mutants is
reduced and less organized, associated to a complete loss of
expression of collagen XIV and tenomodulin as well as a decrease
in the levels of collagen I expression. Here we identiﬁed a novel
gene, betaig-h3, whose expression is enhanced by scleraxis. Betaig-
h3 is a cell adhesion protein expressed in collagen-rich tissues,
including connective tissue, muscle and chondrogenic tissue, where
it interacts with cells and extracellular matrix molecules (Ferguson
et al., 2003).
Several approaches, such as chromatin immunoprecipitation
followed by microarray analyses contributed to identify numerous
direct target genes of MEF2 in Drosophila, highlighting the central role
of MEF2 in myogenesis (Sandmann et al., 2006). Moreover, the
analysis of the control of neural crest development by MEF2C allowed
the identiﬁcation of several homeodomain transcription factors, such
as DLX5 and DLX6, directly activated by MEF2C and synergistically
acting to direct craniofacial development (Verzi et al., 2007). MEF2C
also promotes bone development by activating a network of trans-
cription factors and signaling molecules, including Runx2, a transcrip-
tion factor necessary for chondrocyte hypertrophy, but also directly
activating collagen 10a1 expression (Arnold et al., 2007).
XMEF2C could play a role in two different steps of tendon
development. First, XMEF2C is expressed prior Xscleraxis in progeni-
tors of tendon cells. Potentially, XMEF2C could deﬁne the domain of
scleraxis expression. However, injection of MEF2CGRF induces a
moderate and restricted induction of Xscleraxis in the prescribed
intersomitic region, cells that anyway will express Xscleraxis at later
stages. Ets transcription factors, which are necessary for FGF-mediated
induction, increase scleraxis expression and limit the domain of
scleraxis expression in chick embryo (Brent and Tabin, 2004). The
relationships between Ets and MEF2C transcription factors deserve to
be precisely deﬁned. In a second step, XMEF2C cooperates with
Xscleraxis to speciﬁcally induce the expression of larval tendon genes,
betaig-h3 and tenascin C. As the coinjection of MEF2CGRF and
Xscleraxis induces a strong ectopic expression of these two larval
tendon genes in the whole dorsal embryo region only, we suggest that
the competence of somitic cells is necessary for the cooperation
between XMEF2C and Xscleraxis and that other factors are required to
induce the full differentiation program.
In the present study, using the Xenopus model, we point out an
unexpected function for MEF2C in larval tendon development, distinct
from MEF2A and MEF2D function. XMEF2C might act upstream the
bHLH transcription factor Xscleraxis and both combined activate
speciﬁc genes encoding extracellular matrix proteins. As XMEF2C and
Xscleraxis synergistically induce an ectopic expression of tenascin C in
402 B. della Gaspera et al. / Developmental Biology 328 (2009) 392–402whole dorsal embryo regions including non somitic regions while
XMEF2C or Xscleraxis alone reduces tenascin C expression in somites,
we propose that, during embryogenesis, the coexpression of MEF2C
and scleraxis could contribute to specify a population of somitic cells
to become tendon progenitor cells.
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